Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 19, 2016. The document serves as a transaction notification regarding a specific securities transaction involving a Person Discharging Managerial Responsibilities (PDMR) or a person closely associated with them.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It is a regulatory disclosure of a single transaction event rather than a financial performance report.
Material Changes
No material changes to the company's financial position or operations are reported in this document. The filing details a specific acquisition of ordinary shares by an executive under a deferred bonus plan.
Transaction Details and Commentary
- Transaction Type: Acquisition of Ordinary Shares following the re-investment of dividends paid on July 14, 2016.
- Plan: Deferred Annual Bonus Plan Post-Tax.
- Individual: Ms. C Thomas, SVP, HR.
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Volume: 32,658 shares.
- Price: £16.678 per share.
- Date: July 14, 2016.
- Exchange: London Stock Exchange (XLON).
Investor Verification Points
- Verify the total number of shares held by Ms. C Thomas post-transaction to assess concentration risk or alignment with company performance.
- Confirm the dividend reinvestment terms of the Deferred Annual Bonus Plan Post-Tax to understand the mechanics of the acquisition.
- Check the prevailing market price of GSK shares on July 14, 2016, to validate the transaction price of £16.678.